Treatment Information

Back

Ovarian Cancer treatment details. Biologic therapy.

University of Chicago Medical Center, Chicago, IL, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Chicago, IL
Treatments:Biologic therapyHospital:University of Chicago Medical Center
Drugs:Journal:Link
Date:Apr 2008

Description:

Patients: This phase II study involved thirteen women with ovarian or fallopian tube cancer. The cancer site in the majority (11) patients was the ovary. The median age was 56, ranging from 45 to 70 years old.

Treatment: Patients were treated with the biological therapies bevacizumab and erlotinib.

Toxicity: Two women died during this study, both from gastrointestinal (bowel) perforations. Grade 3 or 4 toxicities (one report of each) were anemia, hypertension, vomiting, and constipation. There were two reports each of grade 3 or 4 diarrhea and nausea.

Results: The median overall survival was 11 months.

Correspondence: Dr. Gini Fleming



Back